A bibliographical search was performed to identify and evaluate the impact in first-episode schizophrenia of the major mortality risk factors as described by the World Health Organisation (2009). We found that at first diagnosis rates of diabetes were only slightly increased, although lipid abnormalities, mild hypertension and being overweight were commonly reported. Levels of drug and alcohol abuse were high, as were pre-diagnosis rates of smoking, physical inactivity and poor cardiorespiratory fitness. During the first year of antipsychotic treatment, there were significant increases in the rates of hyperglycaemia/diabetes, obesity, lipid abnormalities and hypertension, but no changes in fitness levels, smoking or drug and alcohol abuse. In chronic schizophrenia, excess cancer and cardiac deaths seem linked in part to availability and quality of care. Innate risk factors such as abnormal reelin and raised prolactin may also be important. New evidence, such as an inverse relationship between body mass index and suicide in the general population, suggests accepted wisdom may not apply to patients at high risk of ending their own lives. With current knowledge emphasis needs to be placed by early intervention services on physical fitness, smoking and other substance misuse, diabetes and hypertension, as well as focusing on weight reduction only in the obese. has received lecture fees and hospitality from Eli Lilly and Company. Richard Hodgson has received educational support and speaker fees from a number of pharmaceutical companies. Hiram J Wildgust has received lecture and consultancy fees from Eli Lilly and Company.
Introduction
The lifespan of schizophrenia sufferers is shortened by up to 25 years (Kilbourne et al., 2009) . The causes of mortality in schizophrenia are the same as in the general population Leucht et al., 2007; Saha et al., 2007) . The management of these medical comorbidities is complicated by the illness, comorbidity, healthcare professionals' attitudes and healthcare provision.
The World Health Organisation (WHO) reported global mortality risk factors (MRF) in rank order as hypertension, smoking, raised glucose, lack of physical activity, obesity and raised cholesterol above others (WHO, 2009) . These same MRF have been found to be significantly increased in chronic schizophrenia, but there has been little research to establish their individual contribution to all-cause and cardiovascular mortality (Kilbourne et al., 2009; Wildgust and Beary, 2010) . We review the importance of MRF emerging in first-episode schizophrenia (FES) when early interventions could reduce overall mortality.
Method: data sources

Mortality risk factors found in first-episode schizophrenia
We extended a previous literature search on modifiable MRF in FES to September 2010 (Wildgust and Beary, 2010) . Our search strategy was schizophrenia AND mortality AND (modifiable OR intervention OR reduction). Papers were excluded which failed to separate patients with schizophrenia from others unless they included a high percentage of patients with schizophrenia. The search focused on risk factors for mortality and not risk factors for physical ill health. Papers included were limited to systematic reviews, meta-analyses and high-quality studies. In addition, conference proceedings and hand searches were undertaken. The searches were not carried out to the standards of the Moose checklist as only a few contacts were made with authors and no attempt was made to identify unpublished work or search non-English journals.
Results and clinical discussion
Mortality risk factors found in FES
Our initial reported literature search on modifiable MRF in schizophrenia identified 974 papers (Wildgust and Beary, 2010) .The extension to September 2010 identified a further 45 papers. Cochrane systematic reviews on smoking cessation in schizophrenia (Tsoi et al., 2010) and physical healthcare monitoring for patients with serious mental illness (Tosh et al., 2010) were included.
Environmentally and behaviourally induced mortality risk factors. The WHO reported global MRF in rank order as hypertension, smoking, raised glucose, lack of physical activity, obesity and raised cholesterol (WHO, 2009 ) as important targets for preventative health strategies. The frequency and quantitative importance of these risk factors in early schizophrenia is discussed below. In addition, two other potential MRF, drug and alcohol misuse, and antipsychotic medication are reviewed. Table 1 summarises our findings of the rates of these risk factors reported in FES and changes during the first year of treatment. We found no studies which linked these risk factors to mortality risk in FES.
Hypertension. Hypertension is the most important MRF in the general population (Table 1) . Baseline rates of hypertension, when reported, are around the 25% level in modern studies in FES (McEvoy et al., 2007) . Treatment with antipsychotics in FES is associated with significant worsening of hypertension (Table 1) . Clozapine, aripiprazole, olanzapine, quetiapine and risperidone have been associated with hypertension (Taylor et al., 2009) . The CATIE study found in chronic schizophrenia higher prevalence of hypertension (33%) but found few (38%) were being treated (Nasrallah et al., 2006) .
A US study in chronic schizophrenia demonstrated that hypertension is a major risk factor for cardiac mortality (HR = 1.38, 95% CI 1.32-1.46) (Kilbourne et al., 2009) . Hypertension is also associated with stroke mortality in chronic schizophrenia. Reduced stroke mortality was seen in those patients taking antipsychotic medication (Kang et al., 2011) . A Canadian study in psychosis (schizophrenia and non-affective psychosis n = 594) reported higher post-stroke mortality rates for those with schizophrenia (OR = 1.49, 95% CI 1.17-1.88) and significantly fewer medical and surgical interventions (Kisely et al., 2009 ). These different mortality findings associated with stroke in schizophrenia are striking, and may relate to better treatment or other confounders. Screening, diagnosis and active treatment should reduce early mortality, and smoking cessation reduces both heart rate, systolic and diastolic blood pressure (Minami et al., 1999) .
Smoking. Most schizophrenia sufferers begin smoking before diagnosis (Kelly and McCreadie, 1999) (Table 1) . A US study in chronic schizophrenia patients (n = 22,817) followed-up for 8 years showed that smoking (HR = 1.32, 95% CI 1.26-1.39) was the second most important behavioural cardiovascular MRF, behind physical inactivity (HR = 1.66, 95% CI 1.59-1.74) (Kilbourne et al., 2009 ). All-cause mortality in smokers compared with non-smokers in schizophrenia is raised (HR 2.1) (Kelly et al., 2009) . In those patients aged 35-54, smoking increased the risk of cardiac death 12-fold, and overall 43% of patients died of cardiac disease. Smoking in schizophrenia has been associated with a twofold increase in cancer deaths (Tran et al., 2009 ). Miller et al. (2000 found an association between smoking and suicide, but a study of Swedish young men (n = 49,323) followedup for 26 years showed a less robust association (Hemmingsson and Kriebel, 2003) . Passive smoking is now viewed as being almost equally harmful as smoking (Barnoya and Glantz, 2005; Khuder et al., 2007) .
Bupropion has been shown to improve smoking cessation rates in schizophrenia without compromising patients' mental state (Banham and Gilbody, 2010; Tsoi et al., 2010) . However, there is little in the literature to support approaches other than contingent reinforcement with money (Tsoi et al., 2010) . A total smoking ban in a high-security hospital led to no significant negative consequences (Cormac et al., 2010) .
Diabetes mellitus. The risk of developing diabetes was increased in schizophrenia before the introduction of antipsychotics (Kohen, 2004) . Most FES studies show increased rates of glucose abnormalities prior to antipsychotic treatment (Table  1) . Diabetes in 22,817 sufferers of chronic schizophrenia was an important risk factor for cardiac death (HR = 1.51, 95% CI 1.44-1.57) (Kilbourne et al., 2009 ). Vinogradova et al. (2010) reported similar findings, and schizophrenia and diabetes compared with diabetes alone increased mortality rates (HR = 1.84, 95% CI 1.42-2.40).
Managing lifestyle risk factors is associated with an 82% reduction in the risk of type 2 diabetes in people who have a full range of healthy lifestyle factors (Mozaffarian et al., 2009) . Fitness alone reduced the mortality risks associated with diabetes irrespective of body mass index (BMI) (Church et al., 2004) .
Smoking is associated with a 60% increased risk of type 2 diabetes (Willi et al., 2007) . A meta-analysis of 11 studies showed that consuming two or three sugary drinks per day increased the risk of diabetes by 25% (Malik et al., 2010) .
The impact of antipsychotics on the risk of developing diabetes or abnormal glucose levels in FES is an unresolved topic. A review by the World Psychiatric Association (De Hert et al., 2011b) concluded that the inconsistency of findings suggests that medication effects interact with patient, illness, cohort and studyspecific factors.
Antipsychotics, by inducing remission of the psychosis, help patients control their diabetes, as the risk associated with antipsychotics appears to be reduced in patients who are engaged in lifestyle programmes (Menza et al., 2004) . One other important class of drugs which are now recognised as a risk factor for type 2 diabetes are statins (Nielsen et al., 2010; Sattar et al., 2010) . In schizophrenia, lipid-lowering drugs have been associated with a more rapid onset of diabetes than antipsychotics (Table 1) (Nielson et al., 2010) . These drugs are widely used in schizophrenia; recent research suggests that they do not reduce all-cause mortality in primary prevention, and hence they should be restricted to use in secondary prevention .
Physical fitness and activity. We found no studies examining either cardiorespiratory fitness or activity levels in FES. However, a study to investigate physical fitness in teenagers who later developed psychosis found that they were mostly physically inactive (OR = 3.3, 95% CI 1.4-7.9) and had poor cardiorespiratory function (OR = 2.2, 95% CI 0.6-7.8) compared with controls (Koivukangas et al., 2010) . Two studies in chronic schizophrenia supported these findings (Deimel and Lohmann, 1983; Lindamer et al., 2008) . Studies in Scotland and the USA have found that low physical activity was one of the most important behavioural risk factors for cardiac mortality in chronic schizophrenia (Hamer et al., 2008; Kilbourne et al., 2009) . Systematic reviews found little research on improving fitness levels in patients with schizophrenia (Gorczynski and Faulkner, 2010; Vancampfort et al., 2009 ). 
Smoking
Tobacco is ranked as the 2nd most important global mortality risk factor and accounts for 8.7% deaths globally (WHO, 2009) FES Prospective longitudinal study 60% smokers (Barnes et al., 2006) 90% of smokers started before onset of schizophrenia (Kelly and McCreadie, 1999 ) Prospective cohort study with controls 81% smoked vs. 11% controls p < 0.000 (Sengupta et al., 2008) 
Diabetes mellitus
High blood glucose is ranked as the 3rd most important global mortality risk factor and accounts for 5.8% of deaths globally (WHO, 2009) FES baseline data Café study -Prospective Randomised, doubleblind, flexible-dose, multicentre study 4-8% of patients at study entry had fasting levels of glucose > 100 mg/dL (McEvoy et al., 2007) Eufest study Open randomised study 4% and 11% of the patients had hyperglycaemia prior to treatment with antipsychotics (Kahn et al., 2008) Prospective cohort study with controls Similar rates of abnormal blood sugar in FES and controls (Sengupta et al., 2008) 
Chart review
Historical and modern cohort found to have 9% and 2.8%, respectively glucose (≥ 100 mg/dL) (De Hert et al., 2008) 
FES long-term changes
Café study -Prospective Randomised, multicentre study
The number of patients with fasting glucose levels > 100 mg/dL increased across all antipsychotics at 52 weeks (McEvoy et al., 2007) . No significant difference between treatments Eufest study Open randomised study 12 months Mean increase in fasting glucose per month (mm/L) haloperidol (0.04), amisulpride (0.07), olanzapine (0.07), quetiapine (0.06), ziprasidone (0.04) differences not significant (Kahn et al., 2008) Retrospective cohort study Time to diabetes onset was significantly shorter in patients with higher age (hazard ratio (HR): 1.03, confidence interval (CI): 1.02-1.03) and those with 'initial' treatment of olanzapine (HR: 1.41, CI: 1.09-1.83), mid-potency first-generation antipsychotics (HR: 1.60, CI: 1.07-2.39), antihypertensive (HR: 1.87, CI: 1.13-3.09), or lipid-lowering drugs (HR: 4.67, CI: 2.19-10.00). Diabetes mellitus was promoted in patients with schizophrenia by initial treatment with olanzapine (hazard ratio, HR: 1.41) and mid-potency conventional AP (HR: 1.60), as well as by current treatment with low-potency conventional AP (odds ratio, OR: 1.52), olanzapine (Kahn et al., 2008) Randomised double-blind study changes at 12 months and 24 months Mean BMI's of 23.6 and 23.9 (Zipursky et al., 2005) 
Café study -Prospective Randomised, multicentre study 43% of patients gained weight at 52 weeks. % patients gaining ≥ 7% was 80% olanzapine, 58% risperidone and 50% quetiapine (p < 0.05 difference risperidone or quetiapine vs. olanzapine) Eufest study Open randomised study 12-month findings
Overweight category increased to 37% haloperidol, 43% amisulpride, 54% olanzapine, 45% quetiapine and 33% with ziprasidone (p not significant) (Kahn et al., 2008) Randomised double-blind study changes at 12 months and 24 months Virtually all patients treated with olanzapine gained > 7% body weight and 75% of patients treated with haloperidol also gained > 7% body weight. Weight changes not correlated with changes in fasting glucose levels but only with rises in cholesterol at some time points (Zipursky et al., 2005) 
Dyslipidaemia
High cholesterol is ranked as the 6th most important global mortality risk factor and accounts for 4.5% of global deaths (WHO, 2009 LDL levels increased across all treatments but there were no statistically significant differences with mean changes (mmol/L) of LDL of 0.7 for amisulpride, olanzapine and quetiapine, 0.5 for haloperidol and 0.3 for ziprasidone and similar rises for triglyceride levels (Kahn et al., 2008) FES, first-episode schizophrenia; LDL, low-density lipoprotein Psychiatry and medicine have failed to recognise the importance of cardiorespiratory function as a major MRF (Blair, 2009 ). This topic has been comprehensively reviewed (Lee et al., 2010) , linking low cardiorespiratory function to diabetes, hypertension and lipid abnormalities, as well as premature death. Mokdad et al. (2004) estimated that poor diet and inadequate physical activity accounted for 400,000 deaths in the USA in 2000. Khaw et al. (2008) showed smoking avoidance, not being physically inactive, modest alcohol consumption and five portions of fruit and vegetables a day combined to predict a fourfold difference in total mortality with an estimated impact equivalent to 14 years.
Obesity. Weight gain is a major challenge for modern society, yet overall life expectancy paradoxically continues to increase. Weight gain is associated with increased risk for hypertension, diabetes and abnormal lipid levels. It appears that the obese category (BMI > 30) rather than overweight category is the group who are at major mortality risk (Flegal et al., 2007) . Weight gain is a significant issue in longer-term use of all antipsychotics in patients with FES, with large percentages of patients becoming overweight (Table 1 ). In the last 15-20 years, lifestyle factors have not affected the mean BMI of patients when first presenting with schizophrenia (De Hert et al., 2008) . A greater number of comedications and antidepressant medications have been found to be independently associated with weight gain in untreated patients with FES (Strassnig et al., 2007) .
The results of weight management are modest (Bushe et al., 2009; Faulkner et al., 2007) ; however, non-pharmacological approaches have shown benefit in prevention of weight gain (Alvarez-Jiménez et al., 2008; Menza et al., 2004) . Kuk et al. (2006) found that visceral fat was an independent predictor of all-cause mortality. A number of studies in FES report increased amounts of visceral fat (Thakore et al., 2002) , while other studies report no differences (Zhang et al., 2004) . These differences may be explained by different ethnic composition of the populations, different lifestyles and other methodological issues.
There are a number of large long-term epidemiological studies in the general population linking an inverse association of BMI and suicide risk (Bjerkeset et al, 2008; Kaplan et al., 2007a Kaplan et al., , 2007b Magnusson et al., 2006; Mukamal et al., 2007 Mukamal et al., , 2009 Mukamal et al., , 2010 . We identified one study in schizophrenia which linked patients with low BMI to a higher risk of suicide (Limosin et al., 2007) . This is an important topic which has not been reviewed in the schizophrenia literature (Hor and Taylor, 2010; Hawton et al., 2005) . Since suicide is the major cause of death in young patients with schizophrenia, these findings raise concerns about weight loss in the absence of high-quality studies in schizophrenia. Further, there is some evidence that weight loss may not always be beneficial (Sørensen et al, 2005) .
Dyslipidaemia. The importance of abnormal lipids levels
for mortality is shown in Table 1 , together with baseline values in FES. Only some studies show raised levels. Confounding factors such as the size of the study, ethnicity, smoking and diagnostic categories may be relevant. Table 1 also shows in detail the changes in lipid profiles following antipsychotic treatments for 12 months, and in general shows worsening of low-density lipoprotein and triglyceride levels.
It has been estimated that young men who have lower serum cholesterol levels (<5.17 mmol/L) compared with those with higher levels (>6.21mmol/L) have an increase in life expectancy (3.8-8.7 years) (Stamler et al., 2000) . However, a US study of 22,817 patients with chronic schizophrenia followed-up for 8 years found that hyperlipidaemia was associated with a reduced risk of cardiac mortality (HR = 0.88, 95% CI 0.84-0.92) (Kilbourne et al., 2009) .
The complexity of this subject is further illustrated by a metaanalysis of 11 studies on 65,229 primary care patients followedup for 244,000 person-years, finding no evidence of benefit of statin therapy on all-cause mortality in either sex in primary prevention of hypercholesterolemia (Ray et al., 2010) . The Cochrane systematic review on statins found few benefits of statin therapy in primary prevention, as there has been some bias in publishing positive results and a failure to report adverse events Alcohol and drug misuse. Substance abuse leads to an earlier onset of psychosis with a poor prognosis and which is less responsive to antipsychotic treatments (Compton et al., 2009) . Prevalence rates for alcohol and illicit drug use in FES patients are high (Barnett et al., 2007; Kahn et al., 2008) . Amongst antipsychotic drugs, clozapine has shown encouraging results in reducing alcohol (Drake et al., 2000) and substance abuse relapses (Brunette et al., 2006) . This may account to some extent for the reduced mortality of patients with schizophrenia treated with clozapine compared with other antipsychotics (Tiihonen et al., 2009) .
Modern systematic reviews on mortality in schizophrenia have largely failed to consider the contribution of alcohol or drug abuse as a MRF (Leucht et al., 2007; Saha et al., 2007) , but Allgulander (1989) found that illicit drug abuse in schizophrenia was associated with a higher mortality. A 10-year prospective study of 3434 patients with schizophrenia found that illicit drug use was associated with a doubling of the risk for suicide (HR = 2.05, 95%CI 1.29-3.26; p<0.003) but alcohol usage was not (Limosin et al., 2007) . A US study in chronic schizophrenia found that neither hazardous drinking nor illicit drug use were associated with increased cardiac mortality (HR = 0.95, 95% CI 0.90-1.00 and HR = 1.07, 95% CI 0.98-1.16, respectively) (Kilbourne et al., 2009 ). Antipsychotic medication. The use of antipsychotics is an important factor in reducing mortality in schizophrenia (Tiihonen et al., 2006 (Tiihonen et al., , 2009 (Tiihonen et al., , 2011 , but in contrast a systematic review found some evidence that long-term exposure to antipsychotics increases mortality in schizophrenia (Weinmann et al., 2009 ). However, the majority of studies included in this review predate the widespread usage of second-generation antipsychotics. A later review of mortality in schizophrenia found no evidence for increased mortality associated with second-generation antipsychotics . A nationwide study of antipsychotics after first hospitalisation for schizophrenia (Tiihonen et al., 2011) found that the use of any antipsychotic compared with no antipsychotic was linked with lower mortality (adjusted HR = 0.45, 95% CI 0.31-0.67). All-cause and cardiovascular mortality risk associated with antipsychotics was examined by Tiihonen et al. (2009) , and the risk of death was found to be significantly lower in patients on long-term (7-11 years) antipsychotic treatment than in those who had not used any antipsychotic drugs during follow-up (HR= 0·81, 95% CI 0·77 -0·84; p<0·0001). There were no differences for risk of ischaemic heart deaths across antipsychotic classes. This study also found that polypharmacy was not a risk factor for mortality. A Danish study also found that antipsychotic polypharmacy did not contribute to excess mortality, whereas the use of long-half-life benzodiazepines was associated with increased risk of death (Baandrup et al., 2010) . Previous studies of small cohorts (<100 patients) found that polypharmacy associated with firstgeneration antipsychotics was harmful (Joukamaa et al., 2006; Waddington et al., 1998) .
Mortality risk factors present before or at diagnosis of schizophrenia. Historically, schizophrenia was viewed only as a mental disorder; however, there is now sufficient evidence to support the view that it is a multisystem disease (Mitchell and Dinan, 2010) . Potentially, this will help focus management and research in schizophrenia to consider both the physical and mental illness and their linkage.
Establishing the genetic and environmental risk factors for schizophrenia is complex. The gene/environment conundrum is typified by a cardiac mortality study in schizophrenia (Kilbourne et al., 2009) showing an increased risk (HR = 1.17, 95% CI 1.07-1.28) after controlling for sociodemographics, clinical and behavioural factors. In contrast, a study of genetic vulnerability and premature death in schizophrenia spectrum disorders supported the view that environmental factors -and not genetic factors -were responsible for mortality in adoptees (Hakko et al., 2011) .
One potential common pathway for both increased risk of schizophrenia and physical illness is low birth weight, with a UK study finding that patients who developed schizophrenia were more likely to be of low birth weight than controls (p<0.0001 OR = 2.6, 95% CI 2.0-3.3) (Kunugi et al., 2001) . Low birth weight may also be a risk factor or common pathway for the higher incidence of diabetes that was observed in people with schizophrenia and their relatives which predates the introduction of antipsychotics (Kohen, 2004) .
Reduced birth weight in the general population is associated with late-onset diseases including type 2 diabetes, hypertension, and heart disease (Barker et al., 1993) . A number of later studies have confirmed these findings (Forsén et al., 2000; Kuh et al., 2002; Ong, 2006) . Fu et al. (2009) have simulated foetal malnutrition and low birth weight in rats and conclude that their procedure modifies epigenetic characteristics of the rat hepatic IGF-1 gene along the length of the whole gene.
While prolactin levels have been reported as normal in drugnaïve patients (Byerly et al., 2007; Kuruvilla et al., 1992; Segal et al., 2004) , case reports from the nineteenth century of women with schizophrenia frequently report menstrual abnormalities (Kohen and Wildgust, 2008) . Prolactin levels in early schizophrenia have been re-examined and found to be mildly raised in 22% of patients at high risk of psychosis and 27% of antipsychoticnaïve patients (Aston et al., 2010) . The prolactin levels reported by Aston et al. were modestly raised, but results from the US Nurses study (Hankinson et al., 1999; Tworoger et al., 2004 Tworoger et al., , 2007 on the long-term impact of high normal values of prolactin (lower than some of the levels reported by Aston) has raised concerns about an increased risk of breast cancer. Further, a metaanalysis of breast cancer studies in schizophrenia showed a 12% increased risk of breast cancer (Catts et al., 2008) , and a prospective epidemiological study in schizophrenia found an increased standardised mortality ratio (SMR) of 2.8, 95% CI 1.6-4.9 (Tran et al., 2009) .
Abnormalities of lipoprotein receptors can be associated with metabolic changes such as hypercholesterolaemia and shortened lifespan (Rader et al., 2003) . The expression of two receptors for reelin (Fatemi, 2001) , the very low-density lipoprotein receptor (VLDLR) and the apolipoprotein E receptor type 2 (ApoER2), was found to be abnormal in both drug-naïve and medicated patients with schizophrenia. There was a negative correlation between VLDLR mRNA levels and the severity of clinical symptoms. The authors concluded that lipoprotein metabolic differences may be associated with vulnerability to heart disease and premature death.
Shortened telomere length has been proposed as a marker of human ageing (De Meyer et al., 2008), and Fernandez-Egea et al. (2009) have shown that antipsychotic-naïve patients with nonaffective psychosis have reduced telomere length, suggesting a possible vulnerability to premature ageing, although this may be due to many environmental factors including stress and smoking (Epel et al., 2004) . Either interpretation may suggest that schizophrenia is a disorder of accelerated ageing (Kirkpatrick et al., 2008) .
Another stress-related mechanism may be hypercortisolaemia, and a systematic review of cortisol in FES identified seven studies showing significantly raised cortisol levels and one study with normal values (Bradley and Dinan, 2010) . High physical activity and fitness has been shown to minimise the effects of stress on reducing telomere length (Puterman et al., 2010) , whereas people with schizophrenia appear to have low fitness levels (Koivukangas et al., 2010) .
Mortality associated with overt and covert prejudice?
Physical health comorbidities are common in schizophrenia (Dixon et al., 1999; Lambert et al., 2003) . However, patients with established schizophrenia appear to suffer from inequalities in healthcare provision (Lawrence and Kisely, 2010) , and deficits in cardiac care may influence high mortality rates in schizophrenia (Mitchell and Lord, 2010) . A US study in patients with schizophrenia (Katz et al., 1967) found higher cancer mortality rates in those patients with short hospital stays, and Lawrence et al. (2000) reported higher cancer mortality rates in psychiatric patients than in the general population in Western Australia, yet incidence rates were similar. A study in psychiatric patients from Nova Scotia also found an excess mortality for cancer (72% higher in males and 59% higher in females), which could not always be explained by incidence, especially in males (Kisely et al., 2008) . Patients with serious mental illness also appear disadvantaged in accessing mammographic screening (Werneke et al., 2006) . When cardiovascular disease is considered, then patients with schizophrenia receive sub-optimal care at all levels of intervention, from the prescription of statins through to access to surgical procedures (Kisely et al., 2009; Laursen et al., 2009; Mitchell and Lord, 2010) .
The findings from these studies support the view that excess mortality may be attributable to inequitable access to health screening, medical treatments and procedures, not simply increased incidence rates of diseases. It will be important to determine which of these factors apply in practice, as there will be implications for primary and secondary health service provision. We found no research in FES exploring overt or covert prejudice and mortality, a suitable topic for further study which might inform future practice.
Emerging clinical and research implications
Our review identified limited data relating well-established MRF in chronic schizophrenia and the general population, but we were unable to find studies in FES which have examined the impact of these risk factors on either cardiovascular or all-cause mortality. Moreover, there are almost no prospective data in respect of specific approaches in schizophrenia which can improve life expectancy. A further limitation of our understanding of mortality in schizophrenia is that most reviews have not adequately considered the impact of comorbid drugs and alcohol, or smoking (Saha et al., 2007) , all major comorbidities in FES. Mortality as an outcome measure will be valuable in long-term studies following patients with FES.
In FES, a pragmatic approach is to utilise published guidelines for monitoring and managing physical health. , 2011a NICE, 2002a NICE, , 2002b . These guidelines, however, are based on expert consensus and clinical experience rather than high-quality evidence from randomised controlled trials (Tosh et al., 2010; Wildgust and Beary, 2010) . Systematic reviews in chronic schizophrenia for smoking cessation and weight management (Tosi et al., 2010; Faulkner et al., 2007) show disappointing results. Likewise, systematic reviews on fitness in schizophrenia demonstrate that little research in this area has been completed ( Gorczynski and Faulkner, 2010) . These findings illustrate the major challenge to reducing these major MRF in FES. Table 2 summarises our findings for an evidence base for MRF and the management of the four most important global MRF for all-cause mortality in the general population (WHO, 2009) and in schizophrenia. As the evidence base in schizophrenia is poor, we must assume at the moment that the same factors apply in FES. Emphasis needs to be on smoking cessation, hypertension, diabetes and cardiorespiratory fitness rather than on weight, as body mass appears to be inversely related to suicide, the major cause of death in younger patients.
Long-term epidemiological and interventional studies are required to assess these MRF in FES and develop evidence-based treatments. The OPUS programme is such an example; it puts physical activity at the heart of its approach, and is creating a great deal of interest (Frederic, 2010) . In the general population, healthy lifestyle changes can increase lifespan by up to 14 years (Khaw et al., 2008) , and four healthy behaviours reduce the risk of developing diabetes by 80% (Mozaffarian et al., 2009 ); hence it would seem sensible to adopt these protective strategies in schizophrenia management. An important finding specific to schizophrenia is the increased mortality from cardiovascular disease and cancer which is not due to increased incidence of disease, but rather to a failure to receive or accept appropriate treatment. It behoves mental health workers to be systematic in both being advocates for their patients for physical healthcare as well as for screening interventions (Hodgson et al., 2010) . (2009) cohort study c) Myers et al., (2002) randomised controlled trial d) Kodama et al., (2009) meta-analysis e) Fogelholm (2010) meta (2010) Cochrane review -three studies b) Vancampfort et al., (2009) review of 13 studies Need for large long-prospective studies Proposed tactics to reduce excess mortality in schizophrenia (no outcome data have yet been published on these approaches) a) Screen for hypertension at initial diagnosis and then yearly or on medication change a) If smoker, refer patient to smoking cessation clinic, engage carer b) Patient areas need to be smoke free a) Monitor baseline blood glucose and if abnormal, refer to diabetic nurse who is well established at managing these patients. Assess annually or on changing of treatment, or symptoms a) Assess baseline fitness, either simple walking test, or more complex Eurofit assessment. Engage carer in the process and encourage patient to take up fitness activities which appeal to them. Motivation is likely to be a key factor. Dedicated fitness team member
References
